VeriSIM Life Acquires Molomics Biotech

Kiromic Biopharma Acquires InSilico Solutions

July 26, 2021

Biotechnology

Kiromic Biopharma completed the acquisition of InSilico Solutions via a stock-swap, bringing an in‑house bioinformatics and AI team to support development of its outpatient allogeneic CAR‑T therapies for solid tumors. The deal transfers InSilico’s staff and intellectual assets to Kiromic and is intended to accelerate target/biomarker discovery, manufacturing and clinical development.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

ZS Acquires Intomics A/S

May 4, 2022

Biotechnology

ZS, a global professional services firm, has acquired Copenhagen-based bioinformatics and systems biology company Intomics A/S. The 42-person team and Intomics' curated protein-protein interaction network and analytics capabilities will expand ZS's drug discovery, bioinformatics and R&D offerings to better serve pharmaceutical, biotech and research clients.

Evotec SE Makes Strategic Equity Investment in IMIDomics, Inc.

February 15, 2022

Biotechnology

Evotec SE has made a minority equity investment in IMIDomics, Inc., and will take a board seat as part of the transaction; financial terms were not disclosed. The investment is intended to advance IMIDomics' Precision Discovery Engine and strengthen collaboration between Evotec and IMIDomics on data-driven drug discovery for immune-mediated inflammatory diseases.

Calibre Scientific Acquires MoBiTec GmbH

January 15, 2024

Biotechnology

Calibre Scientific has acquired MoBiTec GmbH, a German supplier of consumables and services for molecular and cell biology. MoBiTec will be integrated into BIOZOL Diagnostica GmbH (a Calibre subsidiary) to broaden BIOZOL's product range and strengthen the group's capabilities and sales presence in the DACH research, diagnostics, and pharmaceutical markets.